Wybierz swoją lokalizację, abyśmy mogli dostosować dla Ciebie wyniki wyszukiwania.

Zapamiętaj moją lokalizację oraz ustawienia językowe.

Najnowsze poglądy na temat biofarmaceutyków

Branże biotechnologii oraz farmaceutyki kontynuują swoją szybką ewolucję cyfrową. Siły geopolityczne oraz ekonomiczne stanowią jednak dla nich przeszkody, które wymagają precyzyjnej strategii w całym łańcuchu dostaw. Poznaj świadome przywództwo BCG w dziedzinie biofarmaceutyków, by uzyskać informacje na temat przyszłości branży biotechnologicznej.


Featured Insights

Chasing Value as AI Transforms Health Care

Chasing Value as AI Transforms Health Care

The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.

Biopharmaceuticals - Getting a Grip on COGS in Generic Drugs

Getting a Grip on COGS in Generic Drugs

BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.

How US Tax Reform Will Affect Biopharma Supply Chains

Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.

Placing Your CAR-T Bets

Placing Your CAR-T Bets

These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.

What is the Right Amount to Spend on Biopharma R&D?

What Is the Right Amount to Spend on Biopharma R&D?

The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.

Accelerating Drug Development Today

Accelerating Drug Development Today

BCG GAMMA's Transformative Work for an Oncology Center

Using Big Data to Help Fight Cancer

Innovation in Biopharma R&D

Zewnętrzne podstawy innowacji oczami specjalisty ds. badań i rozwoju

Karalee Close on The Digital Opportunity in Healthcare

Frank Cordes on The Pharma Factory of the Future

Mark Lubkeman on A Return to Growth

protected by reCaptcha

Subscribe to our Biopharma eAlert.

Produkty biofarmaceutyczne

SUBSCRIBE

PL